SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.80-0.1%Nov 21 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (6796)7/25/1998 10:28:00 PM
From: aknahow  Read Replies (1) of 17367
 
Bob, think RobertS would care about Bayer's estimate of the hospital cost in the U.S. for survivors of present ineffective treatments? Naw, his objective was something else, but just in case one does not read the prior post with care, here it is:

"Those that
survive, generally require about two weeks of intensive-care hospitalisation,
at a cost of more than US dollars 5 billion per year in the United States
alone."

Gee, think there will be a market for Neuprex if it works?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News